Moleculin Biotech, Inc., a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, today announced that 14 qualified cancer clinics have requested to participate in its clinical trial to study Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (“AML”).
